Clinical Trials · NCT07000955
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
- Phase
- Phase 1/Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 98
- Start date
- Jun 2025
- Locations
- 1 site, China
- Primary endpoint
- The Incidence of adverse events and serious adverse events during the treatment period